Prenetics Global Limited (NASDAQ:PRE) saw its shares climb 16% on Friday following an announcement that its board has authorized a share repurchase program of up to $40 million to be executed over the next 12 months.
The company, which operates in health sciences and is the parent of the IM8 premium health and longevity brand, said the decision to repurchase shares reflects managements assessment that the current market price does not fully capture the businesss underlying value. The buyback may be carried out through open market purchases, privately negotiated transactions, or block purchases, subject to federal securities laws. The program may be modified, suspended or discontinued at any time.
During the trading week of February 23 to 27, members of Prenetics executive team made open market purchases totaling about $1.3 million at an average price of approximately $17.11 per share. CEO Danny Yeung personally bought roughly $750,000 of stock within that window. Those purchases follow roughly $1.45 million in insider buying after the companys prior earnings release in November 2025. Combined, executives have contributed approximately $2.75 million in personal capital to the company's shares across two consecutive post-earnings trading windows.
Financially, Prenetics reported total adjusted liquidity of around $164 million as of March 1 and stated it carries zero debt on its balance sheet. The company laid out operational targets for its IM8 brand, which is aiming for $180 million to $200 million in revenue for 2026 and anticipates reaching adjusted EBITDA profitability by the fourth quarter of 2027.
In addition to the buyback and internal purchases, Prenetics completed three strategic divestitures during 2025 and into early 2026. These included the sale of ACT Genomics to Delta Electronics for up to approximately $72 million in cash, the sale of the Europa Distribution Business for up to $13 million in stock consideration, and the sale of a 35% equity stake in Insighta to Tencent for $70 million in cash.
Market capitalization for Prenetics stands at about $290 million. The company noted that repurchases will be conducted in compliance with applicable federal securities laws and reiterated that the repurchase program is subject to change, including potential suspension or termination.
Summary
Prenetics authorized a $40 million share buyback and disclosed recent insider purchases, a solid adjusted liquidity position with no debt, explicit IM8 revenue and profitability goals, and the completion of three material divestitures. The board said the repurchase program reflects a view that the share price materially undervalues the company.
Key points
- Board-approved $40 million repurchase program over 12 months helped lift shares by 16%.
- Executives, including the CEO, bought roughly $2.75 million in company stock across two post-earnings windows (about $1.3 million in the week of Feb. 23-27 and $1.45 million after the Nov. 2025 earnings release), indicating management conviction.
- P&L and balance sheet details: approximately $164 million in adjusted liquidity as of March 1, zero debt, and IM8 targets of $180-$200 million revenue in 2026 with adjusted EBITDA profitability expected by Q4 2027. Completed divestitures total consideration up to the reported amounts.
Risks and uncertainties
- The repurchase program may be modified, suspended or discontinued at any time, introducing execution uncertainty for buyback plans - relevant to equity markets and corporate finance activity.
- Several divestiture transactions carry "up to" qualifiers on consideration amounts, indicating that final proceeds may vary from the maximums cited - relevant to the companys reported liquidity and cash position.
- The IM8 revenue and adjusted EBITDA targets represent company guidance and a planned timeline to profitability; these are forward-looking objectives rather than guaranteed outcomes - relevant to investors assessing operational performance.